Clinical Trials Browser

Phase 3 × Carcinoma, Transitional Cell × disitamab vedotin × Clear all

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Phase 3 Recruiting

Carcinoma, Transitional Cell